back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2022-01-17 19:44 Tx date 2022-01-15 |
$ZYME
Zymeworks Inc. |
Galbraith, Kenneth Harry
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-01-17 19:43 Tx date 2022-01-15 |
$ZYME
Zymeworks Inc. |
Galbraith, Kenneth Harry
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+500,000 vol |
500,000 | |
| Filed 2022-01-17 19:40 Tx date 2022-01-15 |
$ZYME
Zymeworks Inc. |
Galbraith, Kenneth Harry
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-05-26 09:40 Tx date 2021-05-21 |
$PRN
Profound Medical Corp. (formerly Mira IV Acquisition Corp.) |
Galbraith, Kenneth Harry
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$220,799
+10,000 vol $22.08 each |
34,950 | |
| Filed 2020-05-31 12:33 Tx date 2020-05-26 |
$LMNL
Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.) |
Galbraith, Kenneth Harry
4 - Director of Issuer
Direct Ownership
|
Options
97 - Other
|
$13,497,354
+887,400 vol $15.21 each |
887,684 | |
| Filed 2020-05-31 12:31 Tx date 2020-05-26 |
$LMNL
Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.) |
Galbraith, Kenneth Harry
4 - Director of Issuer
Direct Ownership
|
Options
97 - Other
|
$-31,946,400
-887,400 vol $36.00 each |
284 | |
| Filed 2020-05-20 13:57 Tx date 2020-05-20 |
$PRN
Profound Medical Corp. (formerly Mira IV Acquisition Corp.) |
Galbraith, Kenneth Harry
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$174,400
+10,000 vol $17.44 each |
24,950 | |
| Filed 2020-01-09 15:50 Tx date 2019-10-11 |
$PRN
Profound Medical Corp. (formerly Mira IV Acquisition Corp.) |
Galbraith, Kenneth Harry
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-44,550 vol |
4,950 | |
| Filed 2019-12-12 16:33 Tx date 2019-12-12 |
$LMNL
Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.) |
Galbraith, Kenneth Harry
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-886,796,392 vol |
887,684 | |
| Filed 2019-11-20 10:56 Tx date 2019-11-18 |
$PRN
Profound Medical Corp. (formerly Mira IV Acquisition Corp.) |
Galbraith, Kenneth Harry
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$112,300
+10,000 vol $11.23 each |
59,500 | |
| Filed 2019-06-07 16:32 Tx date 2019-06-04 |
$PLI
Prometic Life Sciences Inc. |
Galbraith, Kenneth Harry
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$31,946,399
+887,400,000 vol $0.036 each |
887,684,076 | |
| Filed 2018-12-07 Tx date 2018-12-04 |
$PLI
Prometic Life Sciences Inc. |
Galbraith, Kenneth Harry
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$139,999
+181,818 vol $0.77 each |
284,076 | |
| Filed 2018-06-18 Tx date 2018-06-14 |
$PRN
Profound Medical Corp. (formerly Mira IV Acquisition Corp.) |
Galbraith, Kenneth Harry
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$16,830
+16,500 vol $1.02 each |
49,500 | |
| Filed 2017-05-23 Tx date 2017-05-18 |
$PLI
ProMetic Life Sciences Inc. |
Galbraith, Kenneth Harry
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$143,579
+69,362 vol $2.07 each |
102,258 | |
| Filed 2017-04-26 Tx date 2017-04-25 |
$PRN
Profound Medical Corp. (formerly Mira IV Acquisition Corp.) |
Galbraith, Kenneth Harry
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$32,010
+33,000 vol $0.97 each |
33,000 | |
| Filed 2017-04-26 Tx date 2017-01-17 |
$PRN
Profound Medical Corp. (formerly Mira IV Acquisition Corp.) |
Galbraith, Kenneth Harry
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-09-07 Tx date 2016-09-02 |
$PLI
ProMetic Life Sciences Inc. |
Galbraith, Kenneth Harry
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$92,108
+32,896 vol $2.80 each |
32,896 | |
| Filed 2016-08-12 Tx date 2016-08-10 |
$PLI
ProMetic Life Sciences Inc. |
Galbraith, Kenneth Harry
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|